Gemcitabine is a nucleoside analog that is indicated in the treatment of pancreatic cancer. In
order to provide a better use of this drug, the search for immunohistological markers is a hot …

Gemcitabine is one of the most used anti-neoplastic drugs with documented activity in
almost all major localizations of cancer. In pancreatic cancer treatment, gemcitabine …

Purpose The aim of this study was to evaluate efficacy and safety of gemcitabine plus S-1
(GS) combination chemotherapy in patients with unresectable pancreatic cancer. Methods …

Objective: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for
advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine …

Background The role of human equilibrative nucleoside transporter 1 (hENT1) as a
predictive biomarker for gemcitabine efficacy in advanced pancreatic cancer remains …

Results of surgery alone for pancreatic cancer are disappointing. We retrospectively
evaluated the efficacy and tolerability of neoadjuvant chemotherapy (NAC) with gemcitabine …

Abstract Background and Objective Gemcitabine (2′, 2'-difluorodeoxycytidine) is an
anticancer drug, which is effective against solid tumours, including non-small-cell lung …

Although the combination of cisplatin and gemcitabine (GEM) is considered the standard
first-line chemotherapy against unresectable hilar cholangiocarcinoma (HC), its efficacy is …

LY2334737, an oral prodrug of gemcitabine, is cleaved in vivo, releasing gemcitabine and
valproic acid. Oral dosing of mice results in absorption of intact prodrug with slow systemic …

Background The clinical value and predictors of a favorable histological response to
preoperative chemoradiotherapy (CRT) in pancreatic ductal adenocarcinoma (PDAC) …